Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Vaxart, Inc.
  6. News
  7. Summary
    VXRT   US92243A2006

VAXART, INC.

(VXRT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Vaxart New Drug Application for S-Only Tablet Covid-19 Vaccine Candidate Cleared by FDA

08/02/2021 | 08:38am EDT

By Robb M. Stewart

Vaxart Inc. will begin a clinical trial of its S-only oral tablet Covid-19 vaccine candidate in the second half of the year after the U.S. Food and Drug Administration cleared its investigational new drug application.

The biotechnology company on Monday said preliminary data from a non-human primate study indicates that the S-only vaccine produced much higher serum antibodies than the one expressing both S and N proteins. A planned Phase 2 trial would allow Vaxart to compare the S-only and S+N vaccine candidates to help decide which approach offers the best way forward in its Covid-19 vaccine-development program, particularly given emerging variant strains.

In premarket trading, Vaxart's shares were 14% higher after ending Friday at $7.19, up 26% since the end of last year.

In February, Vaxart said it had completed a Phase 1 clinical trial for its oral S+N COVID-19 vaccine, the results of which found that the investigational oral vaccine triggered multiple immune responses against SARS-CoV-2 antigens, while reaching primary and secondary endpoints of safety and immunogenicity.

"Our Phase I results from the S+N vaccine candidate showed remarkable T-cell responses and a mucosal antibody response, but not as strong serum antibody responses," said Sean Tucker, Vaxart's chief scientific officer.

The company said the development of the S-only oral tablet and other S-only constructs will proceed in parallel with the S&N construct.

Write to Robb M. Stewart at robb.stewart@wsj.com

(END) Dow Jones Newswires

08-02-21 0837ET

All news about VAXART, INC.
09/16VAXART : Entry into a Material Definitive Agreement (form 8-K/A)
AQ
09/16VAXART, INC. : Entry into a Material Definitive Agreement, Termination of a Mate..
AQ
09/07VAXART : #8239;to Present at the H.C. Wainwright 23rd Annual Global Investment C..
PR
08/23VAXART : Announces Highly Regarded Biotech Executive Julie M. Cherrington, Ph.D...
PU
08/23VAXART, INC. : Change in Directors or Principal Officers, Financial Statements a..
AQ
08/23Vaxart, Inc. Appoints Julie M. Cherrington to the Board of Directors
CI
08/23VAXART : Announces Highly Regarded Biotech Executive Julie M. Cherrington, Ph.D...
PR
08/19Vaxart, Inc. Announces the Creation of an Eight-Member Scientific and Clinica..
CI
08/11INSIDER TRENDS : 90-Days of Insider Buying at Vaxart Interrupted with Share Disp..
MT
08/05VAXART : Management's Discussion and Analysis of Financial Condition and Results..
AQ
More news
Analyst Recommendations on VAXART, INC.
More recommendations
Financials (USD)
Sales 2021 1,76 M - -
Net income 2021 -77,1 M - -
Net Debt 2021 - - -
P/E ratio 2021 -12,1x
Yield 2021 -
Capitalization 1 030 M 1 030 M -
Capi. / Sales 2021 586x
Capi. / Sales 2022 55,8x
Nbr of Employees 28
Free-Float 99,4%
Chart VAXART, INC.
Duration : Period :
Vaxart, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VAXART, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 8,22 $
Average target price 12,50 $
Spread / Average Target 52,1%
EPS Revisions
Managers and Directors
Andrei Floroiu President CEO, CFO & Director
Todd C. Davis Chairman
Sean N. Tucker Chief Scientific Officer & Senior Vice President
Richard Schwartz Senior Vice President-Technical Operations
Shaily Jaini Garg SVP-Clinical Development & Project Management
Sector and Competitors
1st jan.Capi. (M$)
VAXART, INC.43.96%1 030
GILEAD SCIENCES, INC.22.43%89 973
BIONTECH SE357.13%85 800
REGENERON PHARMACEUTICALS35.20%67 787
WUXI APPTEC CO., LTD.28.41%64 886
VERTEX PHARMACEUTICALS-20.83%48 996